Physician profile
Jamil R Azzi
NPI 1609061415
$81,431.83
in general payments reported to CMS, 2019-2025
16 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,092 · 2023: $8,050 · 2024: $4,535 · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Travel and Lodging: $19K · Honoraria: $2,640 · Food and Beverage: $1,897 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,513.19 |
| Travel and Lodging | $19,435.66 |
| Honoraria | $2,640.00 |
| Food and Beverage | $1,896.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Education | $104.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25,485.83 | 2025 | Gammagard Liquid |
| Vertex Pharmaceuticals Incorporated | $22,778.50 | 2023-2025 | |
| Sobi, INC | $9,960.84 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $4,602.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $3,375.87 | 2024-2025 | |
| Biogen, INC. | $3,189.93 | 2025 | |
| Horizon Therapeutics Plc | $2,928.59 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $2,630.79 | 2025 | Tarpeyo |
| Modernatx, INC. | $2,600.00 | 2023 | |
| Merck Sharp & Dohme LLC | $2,512.08 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $1,091.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $121.36 | 2025 | |
| One Lambda, INC. | $107.76 | 2025 | |
| Mallinckrodt Hospital Products INC. | $28.53 | 2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $17.89 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Azzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.